Signatures of polycomb repression and reduced H3K4 trimethylation are associated with p15INK4b DNA methylation in AML

Area of Science:

• Molecular Biology
• Cancer Epigenetics
• Hematology

Background:

• DNA hypermethylation of the p15INK4b tumor suppressor gene is a frequent event in acute myeloid leukemia (AML).
• Histone modifications play a crucial role in regulating DNA methylation and gene expression, particularly in cancer.
• Understanding these epigenetic alterations is key to developing targeted therapies for AML.

Purpose of the Study:

• To investigate the specific histone modifications at the p15INK4b promoter in AML cells.
• To determine how these histone marks differ between AML cells with and without p15INK4b DNA methylation.
• To assess the reversibility of altered epigenetic patterns using epigenetic drugs.

Main Methods:

• High-density chromatin immunoprecipitation-on-chip (ChIP-on-chip) was employed to map histone modifications.
• Analysis was performed on AML patient blasts and cell lines.
• Treatment with decitabine (5-aza-2'-deoxycytidine) and trichostatin A was used to evaluate drug-induced changes.

Main Results:

• AML cells without p15INK4b DNA methylation exhibit a bivalent histone mark pattern (H3K4me3 and H3K27me3) at the promoter.
• AML cells with p15INK4b DNA methylation lose the active H3K4me3 mark and are exclusively marked by repressive H3K27me3.
• Polycomb repression (H3K27me3 and EZH2) is a common feature across all AML subtypes, regardless of p15INK4b DNA methylation status.
• Epigenetic drug treatment reactivated p15INK4b expression, increased H3K4me3, and maintained H3K27me3 enrichment.

Conclusions:

• AML cells with p15INK4b DNA methylation display distinct histone modification patterns compared to unmethylated cells.
• These epigenetic alterations, including DNA methylation and histone marks, are reversible with epigenetic drug therapy.
• Targeting epigenetic mechanisms offers a promising therapeutic strategy for AML by restoring tumor suppressor gene expression.